National Mutual Insurance Federation of Agricultural Cooperatives Buys 7,000 Shares of Eli Lilly and Company $LLY

National Mutual Insurance Federation of Agricultural Cooperatives lifted its position in Eli Lilly and Company (NYSE:LLY) by 20.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,800 shares of the company’s stock after acquiring an additional 7,000 shares during the period. Eli Lilly and Company makes up approximately 0.3% of National Mutual Insurance Federation of Agricultural Cooperatives’ holdings, making the stock its 24th biggest holding. National Mutual Insurance Federation of Agricultural Cooperatives’ holdings in Eli Lilly and Company were worth $32,584,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the first quarter worth about $27,000. Blume Capital Management Inc. grew its position in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares during the period. IMG Wealth Management Inc. bought a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $35,000. TD Capital Management LLC raised its holdings in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the period. Finally, IMA Advisory Services Inc. bought a new position in Eli Lilly and Company in the first quarter valued at approximately $55,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $987.48 on Wednesday. The stock has a market cap of $933.55 billion, a P/E ratio of 64.54, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a fifty day moving average price of $809.69 and a two-hundred day moving average price of $776.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $999.95. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Guggenheim restated a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. BMO Capital Markets lifted their price target on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday. HSBC boosted their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $981.89.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.